DS-3201b
Showing 1 - 25 of 5,865
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute Trial in United States (DS-3201b)
Terminated
- Leukemia, Myeloid, Acute
- Leukemia, Lymphocytic, Acute
- DS-3201b
-
Boston, Massachusetts
- +5 more
Jun 11, 2021
Adult T-cell Leukemia/Lymphoma Trial in Japan (Valemetostat Tosylate)
Active, not recruiting
- Adult T-cell Leukemia/Lymphoma
- Valemetostat Tosylate
-
Nagoya-shi, Aichi, Japan
- +23 more
Jan 11, 2022
Hepatic Impairment Trial in Miami, Orlando, San Antonio (DS-3201b)
Completed
- Hepatic Impairment
- DS-3201b
-
Miami, Florida
- +2 more
Feb 24, 2021
Lymphoma, B-Cell Trial in Belgium, France (Valemetostat tosylate)
Recruiting
- Lymphoma, B-Cell
- Valemetostat tosylate
-
Bruges, Belgium
- +21 more
Jan 9, 2023
Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma Trial in Worldwide (Valemetostat Tosylate)
Recruiting
- Relapsed/Refractory Peripheral T-Cell Lymphoma
- Adult T Cell Leukemia/Lymphoma
- Valemetostat Tosylate
-
Duarte, California
- +59 more
Jun 3, 2022
Netherton Syndrome Trial in Paris (DS-2325a, Placebo)
Not yet recruiting
- Netherton Syndrome
- DS-2325a
- Placebo
-
Paris, FranceSaint Louis Hospital
Jul 31, 2023
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma Trial
Recruiting
- Aggressive Variant Prostate Carcinoma
- +9 more
- Ipilimumab
- Valemetostat
-
Houston, TexasM D Anderson Cancer Center
Jan 19, 2022
Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus Trial (DS-7011a, Placebo)
Not yet recruiting
- Systemic Lupus Erythematosus
- Cutaneous Lupus Erythematosus
- DS-7011a
- Placebo
- (no location specified)
Dec 12, 2022
Duchenne Muscular Dystrophy Trial in Tokyo, Hyogo, Kobe-shi (DS-5141b)
Active, not recruiting
- Duchenne Muscular Dystrophy
-
Tokyo, Kodaira-Shi, Japan
- +1 more
Mar 2, 2022
Tumor Metastasis Trial in Japan, Korea, Republic of, Taiwan (DS-8201a, Ritonavir, Itraconazole)
Active, not recruiting
- Neoplasm Metastasis
- DS-8201a
- +2 more
-
Sapporo, Hokkaido, Japan
- +9 more
Mar 3, 2022
Hematopoietic and Lymphoid Cell Tumor, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Trial in Houston
Active, not recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +8 more
- DS-1594b
- +14 more
-
Houston, TexasM D Anderson Cancer Center
Oct 6, 2022
Breast Cancer Trial (Trastuzumab Deruxtecan)
Not yet recruiting
- Breast Cancer
- Trastuzumab Deruxtecan
- (no location specified)
Jul 10, 2023
Treatment Optimization of Refractory
Recruiting
- Hepatitis B, Chronic
- Virus Diseases
- original therapy
- rescue therapy
-
Ankang, China
- +12 more
Feb 1, 2023
Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent, Mantle Cell Lymphoma Refractory Trial in Orange,
Recruiting
- Follicular B-cell Non-Hodgkin's Lymphoma
- +7 more
- MB-106
-
Orange, California
- +3 more
Nov 1, 2022
Acute Myeloid Leukemia Trial in United States (Quizartinib, Milademetan)
Terminated
- Acute Myeloid Leukemia
-
Los Angeles, California
- +7 more
Mar 14, 2022
Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer Trial in United States (drug,
Recruiting
- Early-stage Breast Cancer
- +6 more
- Anastrozole
- +2 more
-
Fullerton, California
- +8 more
Sep 19, 2022
Breast Cancer, Non-small Cell Lung Carcinoma Trial in Worldwide (Trastuzumab deruxtecan (DS-8201a), Pembrolizumab)
Recruiting
- Breast Cancer
- Non-small Cell Lung Carcinoma
- Trastuzumab deruxtecan (DS-8201a)
- Pembrolizumab
-
San Francisco, California
- +24 more
Nov 30, 2022
Pulmonary Arterial Hypertension, Pulmonary Hypertension Trial in Canada, United States (Inhaled Nitric Oxide 0.025 mg/kg IBW/hr
Completed
- Pulmonary Arterial Hypertension
- Pulmonary Hypertension
- Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device
- +2 more
-
Birmingham, Alabama
- +50 more
Jul 13, 2022